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ABSTRACT 
Background and aims: Under-reporting of adverse drug reactions (ADRs) by health care 
professionals (HCPs) is a worldwide problem. Spontaneous reporting in hospitals is scarce and 
several obstacles have been identified. Improved hospital-based reports could make important 
contributions to future care. Consequently, the objective of this study was to develop, implement and 
evaluate a structured pharmacist-driven pharmacovigilance (PV) system for in-patient ADR reporting 
in a leading public hospital in South Africa, for future use in South Africa and wider. Method: 
Descriptive, operational intervention study with a pre-post design. Pharmacist-driven interventions 
targeted at ADR reporting were implemented. Convenience sampling was used to recruit HCPs 
(medical practitioners, pharmacists, pharmacist assistants and nurses) to complete a self-
administered questionnaire. The principal outcome measures were the number of the ADRs reported 
for inpatients 18 months prior to and 18 months during the intervention period as well as an evaluation 
of the intervention programme in terms of continuous information and training. Results: Significant 
increase in the number of HCPs reporting an ADR post-intervention (33.8% up from 12.1%; 
p<0.0001). Reasons for non-reporting decreased significantly, e.g. ‘How, where and when to report’ 
an ADR (p=0.0027) and ‘Concern that the report may be wrong’ (p=0.0041). HCPs knowledge of the 
ADR reporting system also improved appreciably apart from pharmacists who were already 
knowledgeable. Conclusion: The results showed the benefits of pharmacist-driven interventions on 
HCPs’ knowledge and awareness of PV and the number of the ADRs reported. Hospital management 
and policy makers should consider the important role pharmacists can play in improving rational and 
safe use of medicines among inpatients, based on appropriate training of HCPs and proper systems. 
As a result, help achieve the standards established by the Department of Health in South Africa. 
 
1. Introduction 
 
Adverse drug reactions (ADRs) have the potential to cause significant harm to patients [1, 2], 
increasing morbidity and mortality, and adding to patient suffering [3-6].  As a result, there is growing 
awareness of the impact of ADRs on patient care and public health [7]. Overall, ADRs are among the 
leading causes of mortality across countries [5, 6, 8, 9], enhanced by an appreciable number of 
hospital admissions each year [10-16] as well as in-patient ADRs [17].  
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Within South Africa, an observational study conducted among medical wards of a secondary hospital 
in the Western Cape estimated that 6.3% of hospitalised patients were admitted as a direct result of 
an ADR, while a further 6.3% of patients developed a significant ADR while in hospital [18]. Another 
cross-sectional survey undertaken over a 30 day period in the medical wards of four hospitals in 
South Africa estimated that ADRs contributed to the death of 2.9% of medical admissions, and 56 of 
357 deaths in the wards (16%) were ADR-related [4]. 
 
As a result of the growing concerns with ADRs, the National Department of Health in South Africa in 
2011 published its National Core Standards (NCS) to improve future quality of care. The reporting of 
ADRs formed part of the safety aspects of the NCS [19]. The National Health Act was subsequently 
amended on 24 July 2013 [20] to establish an independent public entity, the ‘Office of Health 
Standards Compliance’, as a new regulator to protect and promote health and safety in health 
services by monitoring and enforcing compliance within all health establishments using certain norms 
and standards. According to these standards, a clear pharmacovigilance (PV) system must be in 
place in each hospital to monitor and manage ADRs [19,20]. 
 
To date within South Africa, there have been limited studies assessing the extent of ADR reporting 
and PV knowledge among health care professionals (HCPs) following the introduction of the NCS and 
the establishment of the Office of Health Standards Compliance. Prior to 2012, ADRs were also not 
formally reported in Sebokeng Hospital, one of the major secondary care referral public sector 
hospitals in the Gauteng Province, with 800 beds [21]. According to hospital statistics, no ADRs were 
reported between 2012 and November 2013 and only six ADRs were reported between December 
2013 and May 2015 [22].  
 
Pharmacists are typically in a unique situation to collect ADR data in hospitals, which when analysed 
and acted upon should improve the future use of medicines. We previously carried out a study to 
determine possible reasons for the lack of ADR reporting in public hospitals in South Africa [23] as the 
first step to implement and evaluate potential measures within the practice setting to improve both the 
quantity and quality of ADR reporting. Consequently, this study aimed to develop, implement and 
evaluate a structured pharmacist-driven PV system for ADR reporting at Sebokeng Hospital to 
address current concerns with low reporting rates. This manuscript reports on the outcomes of this 
operational process to provide future guidance 
 
2. Methodology 
2.1 Study setting and design 
The study was conducted at Sebokeng Hospital, in the Sedibeng District of the Gauteng Province, 
South Africa [21]. This was a phased, operational, intervention study with a pre- and post-intervention 
comparison, to develop, implement, and evaluate a structured pharmacist-driven PV system for ADR 
reporting, conducted over a period of 20 months between 2015 and 2016. Figure 1 gives a schematic 
representation of the study design and process, which is described in more detail in Section 2.3. 
 
2.2 Study population 
The study population included all medical practitioners, pharmacists, pharmacists’ assistants and 
nurses employed by Sebokeng hospital. At the time of the study, 547 medical practitioners, 
pharmacists, and nurses were employed by the hospital. 
 
2.3 Data collection, sample and intervention 
Phase A (pre-intervention) was an historic one month baseline and needs analysis conducted in 
May 2015, which has already been published [23]. Briefly, a retrospective review of records was 
conducted to determine the number of ADR reports submitted at Sebokeng Hospital for the 18-month 
period prior to the intervention, i.e. from November 2013 to April 2015 [23]. A needs analysis, using a 
self-administered questionnaire, was conducted amongst a convenient sample of 131 HCPs 
regarding structures for, processes followed and outcomes of ADR reporting at the hospital [23].  
 
Phase B (pharmacist-driven intervention) entailed the design and implementation of a pharmacist-
driven PV system, implemented as an intervention by a pharmacist in all the wards to improve ADR 
reporting. The synopsis and findings of the baseline assessment and needs analysis conducted in 
Phase A guided the interventions in Phase B. Due to the operational nature of the project, the 
3 
 
pharmacist continued with, and subsequently monitored the interventions (PV system) in practice, for 
a period of 18 months. This intervention period included various activities carried out by the 
pharmacist in the hospital, including continuous education and training on PV and ADR reporting, 
which took place at different forums in the hospital. Details on the various elements covered by the 
interventions are shown in Figure 1.   
 
Phase C (post-intervention evaluation) was an evaluation of the structured PV system for ADR 
reporting and outcomes. Similar to Phase A, a retrospective review of the records was conducted to 
determine the number of ADR reports submitted during the intervention phase (Phase B). In addition, 
a conveniently selected sample of 151 HCPs, based on similar numbers to Phase A, completed the 
same self-administered questionnaire as in Phase A [23]. There were also additional questions 
specifically related to the interventions and the post-implementation to evaluate the acceptance and 
influence of the implemented PV system. Data collection took place in November 2016 and was 
similar to Phase A [23]. HCPs working in the hospital at the time of data collection were informed of 
the study using general communication to the wards.  
 
As mentioned, convenience sampling was used to invite HCPs present in a particular ward at the time 
of data collection to participate in the study and complete the questionnaire. Written informed consent 
for participation was obtained. After this, HCPs were provided with the aims and objectives of the 
study and informed that their participation was voluntary. The questionnaire was subsequently 
completed in a private area in the ward or pharmacy and placed in a sealed container provided in the 
area. The differences in structures for the processes followed, as well as outcomes of ADR reporting 
prior to and after the implementation of the structured PV system, were determined based on the self-
administered questionnaire results. 
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ADRs: Adverse drug reactions; HCPs: Health care professionals; PV: Pharmacovigilance; SOPs: Standard operating procedures 
Figure 1. Study design and process
PHASE C: Post-intervention 
evaluation 
(One month) 
  
 PHASE B: Implementation and continuation of pharmacist-driven 
interventions (PV system) 
(18 months) 
 Develop and implement a pharmacist-driven structured PV system 
 Continuation in practice of implemented pharmacist-driven structured PV 
system 
  
 Retrospective review of records: 
ADR reports submitted during 18 
months of Phase B 
 Post-implementation self-
administered questionnaire for 
HCPs 
 Determine the number of ADRs 
reported (rate of ADR reporting) 
during the 18 months of Phase B 
 Post-implementation self-
administered questionnaire for 
HCPs: 
 Structures in place for ADR 
reporting   
 Process followed 
 Outcome of ADR reporting 
  
PHASE A: Pre-intervention 
baseline and needs analysis [23]  
(One month)  
 Retrospective review of records: 
ADR reports submitted 18 
months prior to the study 
 Needs analysis with self-
administered questionnaire for 
HCPs 
 Determine the number of ADRs 
reported (rate of ADR reporting) 
18 months prior to the study 
 Needs analysis with a self-
administered questionnaire for 
HCPs: 
 Structures in place for ADR 
reporting   
 Process followed 
 Outcome of ADR reporting 
EVALUATE THE STRUCTURED PHARMACIST-DRIVEN PV SYSTEM 
 Determine the difference in number of ADR reports submitted prior to and post the 
implementation of the structured PV system 
 Determine the difference in structures for, process followed-and outcomes of ADR reporting 
prior to and post the implementation of the structured pharmacist-driven PV system 
Based on the findings of Phase A, the interventions implemented by the 
pharmacist included the following elements: 
 Provide information on the pharmacist-driven structured PV system at the 
relevant forums within the hospital continuously throughout the 18 months  
 Provide interactive training for HCPs and support staff on ADRs, the 
reporting thereof and monitoring it 
 Place posters in wards and other public areas to increase awareness of 
ADR reporting  
 Introduce an applicable referral system and process for ADR reporting in 
the wards and monitoring it 
 Increase accessibility of ADR forms and monitor completion thereof 
 Place an example of a completed ADR form in each ward  
 Create an ADR reporting ‘WhatsApp’ group for HCPs in the hospital 
 Attendance of a pharmacist in the medical ward rounds and active 
involvement in education of healthcare workers 
 Circulate and display SOPs for submission of completed ADR forms 
 Submit completed ADR forms to Provincial and National PV offices and 
authorities 
 Summarise and analyse reported ADRs for feedback to HCPs  
 Monthly feedback on PV system at relevant forums within the hospital  
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2.4 Data analysis 
Data were captured in Microsoft Excel™, proof-read for accuracy and cleaned for statistical analysis 
with SAS, release 9.2, running under Microsoft Windows. Characteristics of HCPs were summarised 
as frequencies and percentages.  
 
The number of ADR reports submitted by the hospital over the 18-month period during the 
intervention phase (Phase B) of the study was determined and compared with the number submitted 
during the 18-month period prior to the implementation of the pharmacist-driven PV system (Phase 
A). Proportions of HCPs with knowledge and attitudes regarding PV and ADR reporting, at baseline 
(Phase A) [23] and post-intervention (Phase C), were compared using a Fisher Exact test, to give an 
indication of statistical significance, where p < 0.05.   
 
2.5 Ethical considerations 
Ethical clearance for the study was obtained from the Medunsa Research Ethics Committee 
(MREC/H/26/2014: PG) of the previous University of Limpopo, now known as Sefako Makgatho 
Health Sciences University, prior to the commencement of the study. Ethical approval was also 
obtained from the Gauteng Provincial Ethics Committee. Permission to conduct the study at 
Sebokeng Hospital was obtained from the Chief Executive Officer (CEO) of Sebokeng Hospital.  
All participants provided written informed consent for participation.  
 
3. Results 
 
3.1 Background characteristics of HCPs 
Overall, 132 HCPs took part pre-intervention (Phase A) [23] and 151 post-intervention (Phase C). 
Characteristics of HCPs who participated in the pre-intervention and post-intervention phases are 
contained in Table 1.  
 
Table 1. Background characteristics of HCPs 
Background characteristics 
Phase A: Pre-
intervention (n=132) 
Phase C: Post-
intervention (n=151) 
Number % Number % 
Age (years) 
21-30 39 29.5 41 27.2 
31-40 29 22.0 41 27.2 
41-50 30 22.7 40 26.5 
51-60 27 20.5 28 18.5 
>61 7 5.3 1 0.7 
Gender 
Male 30 22.7 43 28.5 
Female 102 77.3 108 71.5 
Health care 
professional  
Medical Practitioner 31 24.0 61 40.4 
Pharmacist 9 7.0 15 9.9 
Pharmacist Assistant 15 11.0 22 14.6 
Nurse 77 58.0 50 33.1 
Other 0 0 3 2.0 
Pre-intervention: Findings from Phase A [23]; Post-intervention: Findings from Phase C  
 
Amongst the HCPs, there were more medical practitioners (61) who completed the post-intervention 
questionnaire compared to the 31 in the first phase, whereas the number of nurses participating 
decreased from 77 to 50. 
 
3.2 Training and practice on ADR reporting 
Data concerning training and practice regarding ADRs are presented in Table 2. Five (5.3%) HCPs 
indicated that they had received training on ADR reporting prior to the intervention and 89.4% of 
HCPs indicated that they would like to receive training (Phase A). After the multiple activities (Phase 
B), 32.5% indicated that they have received training during the intervention, although 88.7% would 
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like to receive further training. However, the number of HCPs reporting any ADR significantly 
increased from 12.1% to 33.8% post the interventions. 
 
Table 2. Training and practice on ADR reporting 
  
 
Healthcare professionals; n (%) 
Medical 
Practitioner 
Pharmacist 
Pharmacist 
Assistant 
Nurse Other Total 
Sample size (n) 
Pre 31 9 15 77 0 132 
Post 61 15 22 50 0 151 
Received training on 
ADR reporting 
Pre 0 
2  
(22.2%) 
4  
(26.7%) 
1  
(1.3%) 
0 7  
(5.3%) 
Post 
12  
(19.7%) 
13  
(86.7%) 
10  
(45.5%) 
14 
(28.0%) 
0 
49 
(32.5%) 
p 0.0070 0.0030 0.3136 <0.0001 n/a  
Would like to receive 
training on ADR 
reporting 
Pre 
30  
(96.8%) 
9  
(100%) 
14  
(93.3%) 
65 
(84.4%) 
0 118 
(89.4%) 
Post 
54  
(88.5%) 
13  
(86.7%) 
18  
(81.8%) 
46 
(92.0%) 
3 
(100%) 
134 
(88.7%) 
p 0.2589 0.5109 0.6290 0.2776 n/a  
Reported any 
suspected ADR  
Pre 
4  
(12.9%) 
5  
(55.6%) 
0 
7  
(9.1%) 
0 16 
(12.1%) 
Post 
17  
(27.9%) 
15  
(100%) 
7  
(31.8%) 
12  
(24%) 
0 
51 
(33.8%) 
p 0.1230 0.0119 0.0279 0.0393 n/a <0.0001 
Pre: Findings from Phase A [23]; Post: Findings from Phase C  
 
3.3 Reasons for not reporting ADRs 
Reasons given by HCPs for not reporting ADRs are presented in Figure 2. Prior to the intervention, 
the most prominent reasons for not reporting ADRs (54.5%) were that they did not know how to 
report, where to report, and when to report ADRs. This decreased to 36.4% post-intervention 
(p=0.0057) (Figure 2). ‘Concern that the report may be wrong’ decreased from 34.1% to 18.7% post-
intervention (p=0.0041). However, there were no significant changes in a number of the other 
categories including ‘nothing would be done with the data’ and the ‘medical practitioners’ lack of time 
to look actively for ADRs’ while on the ward.   
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Figure 2. Reasons for not reporting ADRs 
 
Pre-intervention: Findings from Phase A [23]; Post-intervention: Findings from Phase C  
 
3.4 Knowledge and attitudes regarding ADR reporting 
Table 3 presents data for changes in knowledge from baseline assessments as well as attitudes 
before the intervention (Phase A) and after training was undertaken during the various interventions.  
 
The interventions had a signiﬁcant effect on HCPs’ overall perceptions about ADR reporting. HCPs’ 
awareness of an ADR reporting system in the hospital increased significantly following the 
interventions from 18.9% to 70.2% (p<0.0001). Knowledge of the availability of an ADR reporting form 
on the wards also increased significantly from 15.2% to 68.9% (p<0.0001). The vast majority (98.0%) 
of HCPs also believed that it is necessary to report ADRs post the interventional phase (p<0.0001). 
As a result, the reporting of ADRs appreciably increased post intervention (Table 2).  
 
HCPs’ knowledge regarding to whom the completed ADR form must be submitted also appreciably 
improved to 72.8% (p<0.0001). However, HCPs’ perception about their professional obligation to 
report an ADR did not improve signiﬁcantly from the high baseline of 89.4% (Table 3). At baseline, the 
majority of HCPs (82.6%) believed that ADR reporting should be compulsory; this increased to 93.4% 
post-intervention. Pre-intervention (Phase A), 8.3% of HCPs felt that ADR reporting should be 
remunerated, while in the post-intervention questionnaire no respondents indicated that they would 
like to be remunerated when they reported ADRs.  
 
HCPs’ opinion about whose responsibility it is to report ADRs also changed post-intervention. The 
medical practitioner being responsible for ADR reporting post-intervention (87.4%) did not change 
significantly from the high baseline of 85.6%. However, significantly more HCPs perceived it to be 
also the responsibility of the pharmacist (71.9% vs. 84.1%; p=0.0142) and the nurse (85.6% vs. 
93.4%; p=0.0479 to report ADRs (Table 3). 
  
  
36.4
37.8
35.1
38.4
17.9
19.9
18.7
16.6
54.5
37.1
37.1
32.6
22.0
22.0
34.1
22.7
0 10 20 30 40 50 60
How, where, when to report
Lack of time to look for ADRs
Lack of time to complete a report
Nothing done with the data
Lack of confidence to discuss ADR
Reporting generate extra work
Concern report may be wrong
Single  ADR report may not affect database
%  Health care professionals
Pre-intervention (n=132) Post-intervention (n=151)
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Table 3. Knowledge and attitudes regarding ADR reporting before and after the intervention  
  
Healthcare professionals; n (%) 
Medical 
Practitioner 
Pharmacist 
Pharmacist 
Assistant 
Nurse Other Total 
Sample size (n) Pre 31 9 15 77 0 132 
Post 61 15 22 50 3 151 
Aware of an 
ADR reporting 
system in 
Sebokeng 
Hospital 
Pre 
2  
(6.5%) 
8  
(88.9%) 
5  
(33.3%) 
10  
(12.9%) 
0 
25  
(18.9%) 
Post 
32  
(52.5%) 
15  
(100%) 
16  
(72.7%) 
42  
(84%) 
1 
(33.3%) 
106 
(70.2%) 
p <0.0001 0.3750 0.0233 <0.0001 NA <0.0001 
Know of an 
ADR reporting 
form available 
in the ward or 
hospital 
Pre 
4  
(12.9%) 
2  
(22.2%) 
8  
(53.3%) 
6 
 (7.8%) 
0 
20  
(15.2%) 
Post 
27  
(44.3%) 
15  
(100%) 
19  
(86.4%) 
43  
(86%) 
0 
104 
(68.9%) 
P 0.0025 0.3750 0.0563 <0.00001 NA <0.0001 
Necessary to 
report ADRs 
Pre 
31  
(100%) 
9  
(100%) 
14  
(19.3%) 
7  
(94.8%) 
0 
61  
(46.2%) 
Post 
60  
(98.4%) 
15  
(100%) 
20  
(90.9%) 
50  
(100%) 
3  
(100%) 
148  
(98.0%) 
p 1.0000 NA 1.0000 0.1532 NA <0.0001 
Know to whom 
the completed 
ADR form must 
be submitted 
Pre 
4  
(12.9%) 
6  
(66.7%) 
3  
(20.0%) 
12  
(15.6%) 
0 
25  
(18.9%) 
Post 
45  
(73.8%) 
15  
(100%) 
12  
(54.5%) 
35  
(70.0%) 
3  
(100%) 
110 
(72.8%) 
p <0.0001 0.0415 0.0471 <0.0001 NA <0.0001 
ADR reporting 
is a 
professional 
obligation 
Pre 
31  
(100%) 
9  
(100%) 
11  
(73.7%) 
67 
 (87.0%) 
0 
118 
(89.4%) 
Post 
59  
(96.7%) 
15  
(100%) 
18  
(81.8%) 
45  
(90.0%) 
3 
(100%) 
140 
(92.7%) 
p 0.5483 NA 0.6897 0.7803 NA 0.4023 
R
e
s
p
o
n
s
ib
il
it
y
 t
o
 r
e
p
o
rt
 a
n
 A
D
R
 
M
e
d
ic
a
l 
P
ra
c
ti
ti
o
n
e
r 
Pre 
30  
(96.8%) 
9  
(100%) 
12  
(80%) 
62 
 (80.3%) 
0 
113 
(85.6%) 
Post 
60  
(98.4%) 
15  
(100%) 
19  
(86.4%) 
35  
(70.0%) 
3  
(100%) 
132 
(87.4%) 
p 1.0000 NA 0.6696 0.2023 NA 0.7278 
P
h
a
rm
a
c
is
t 
Pre 
29 
(93.5%) 
8  
(88.9%) 
12  
(80.0%) 
46  
(59.7%) 
0 
95  
(71.9%) 
Post 
54 
(88.5%) 
15  
(100%) 
21  
(95.5%) 
34  
(68.0%) 
3  
(100%) 
127 
(84.1%) 
p 0.7127 0.3750 0.2830 0.4521 NA 0.0142 
N
u
rs
e
 Pre 
29  
(93.5%) 
9 (100%) 13 (86.7%) 
62 
(80.5%) 
0 
113 
(85.6%) 
Post 
57  
(93.4%) 
15  
(100%) 
20  
(90.9%) 
46  
(92.0%) 
3  
(100%) 
141 
(93.4%) 
p 1.0000 NA 1.0000 0.1248 NA 0.0479 
Pre: Findings from Phase A [23]; Post: Findings from Phase C  
 
3.5 Knowledge about ADR reporting for medicines and events 
Knowledge about ADR reporting among HCPs is shown in Table 4. A significantly increased 
awareness was seen regarding knowledge about the reporting of ADRs from allopathic medicines, 
herbal medicines and blood products. The reporting of any suspected ADR, unusual event, and death 
due to a suspected ADR or congenital anomaly also increased significantly. 
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Table 4. Knowledge of HCPs about ADR reporting for medicines and events pre- and post-
intervention 
 
Reasons 
Pre-intervention 
(n=132) 
Post-intervention 
(n=151) 
p 
Categories of medicines for which ADRs should be reported 
Allopathic medicines 78 (59.1%) 108 (72.0%) 0.0240 
Herbal medicines 87 (66.0%) 121 (80.1%) 0.0100 
Blood products 120 (91.0%) 146 (96.7%) 0.0473 
Vaccines 125 (94.7%) 144 (95.4%) 1.0000 
Biological products 112 (84.1%) 137 (90.7%) 0.1451 
Medical devices 111 (84.1%) 128 (84.8%) 1.0000 
Traditional and complementary medicines 93 (70.5%) 119 (78.8%) 0.1305 
Events which should be reported 
Reaction to a new drug 121 (91.7%) 144 (95.4%) 0.2293 
Serious event 120 (90.9%) 140 (92.7%) 0.6648 
Unusual event 104 (78.8%) 139 (92.1%) 0.0019 
Well-recognized adverse reaction of a drug 112 (84.8%) 131 (86.8% 0.7330 
Any suspected drug interaction 114 (86.4%) 143 (94.7%) 0.0220 
Death of patient due to a suspected interaction 114 (86.4%) 142 (94.0%) 0.0411 
Congenital anomaly 94 (71.2%) 128 (84.8%) 0.0061 
Pre: Findings from Phase A [23]; Post: Findings from Phase C  
 
3.6 Experience of HCPs with the pharmacist-driven PV system  
Responses of HCPs regarding the elements of the PV system, post-intervention, are summarised in 
Table 5. 
 
Table 5. Experience of HCPs with the pharmacist-driven PV system as reported post-
intervention 
 
Experience with the pharmacist-driven pharmacovigilance 
system 
Health care 
professionals (n=151) 
A pharmacist-driven ADR system will be supported 145 (96.0%) 
Importance of ADR reporting is understood as a result of posters 
and training 
128 (84.8%) 
The standard operating procedure assisted in ADR reporting 83 (55.0%) 
Posters referring to ADR reporting placed in the wards were noticed 79 (52.3%) 
The box with ADR forms placed in the ward was noticed 66 (43.7%) 
Completed example ADR form displayed in the ward were used 54 (35.8%) 
Submitted an ADR report as a direct result of training received 40 (26.5%) 
ADR reports were submitted as a result of the posters 32 (21.2%) 
 
3.7 Number of ADRs reported 
In the 18 months before the intervention, a total of six ADR reports were submitted. Since the 
implementation of the intervention, a total of 69 ADR reports were submitted during Phase B. Forty of 
the 69 reported ADRs (58.0%) were a direct result of the training, as indicted by 40 of the 151 
respondents post-intervention (Table 5). However, the number of ADRs reported per HCP is 
unknown, hence one HCP might have reported more than one ADR.  
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4. Discussion 
We believe this is the ﬁrst study in this province of South Africa to evaluate an intervention 
programme aimed at improving ADR reporting and HCPs’ knowledge, attitudes and perceptions 
regarding ADRs, and also potentially within public hospitals in South Africa since the amendments to 
the National Health Act in 2013 [20].  
 
The results from Phase A showed that 88% of HCPs had never reported an ADR despite the 
introduction of the NCS in 2011 [23], with this high rate of non-reporting similar to a tertiary centre in 
Nigeria (86.2%) [24] and in India where only 22.8% of HCPs had ever reported an ADR [25]. The rate 
of non-reporting was significantly reduced following the interventions (Table 2), with 33.8% of HCPs 
indicating they had now reported an ADR. However, we believe this figure can be further increased 
since in a teaching referral hospital in Tehran, Iran, 84.1% of HCPs had recognised ADRs previously 
while 89% identiﬁed ADRs following interventions [26]. 
 
Only 19% of our respondents were aware of the existing ADR reporting system prior to the 
interventions, much lower than the 55.4% seen by Fadare et al. [24].  This changed following the 
intervention to 70.2% (Table 3), similar to the results of a study undertaken in Ghana, which found 
that 71.5% of the HCPs were aware of the reporting system after an intervention [27]. 
 
After the intervention, the most prominent reasons for reporting were still reactions to a new drug 
(95.4%) (Table 4). However, an improvement was that HCPs would now report any suspected drug 
interaction (94.7%), with a significant improvement in the likely reporting of ADRs from allopathic and 
herbal medicines and blood products (Table 4). Similar results were reported in a study conducted in 
a teaching hospital in Lagos, Nigeria, where respondents were encouraged to report ADRs if the 
reaction was serious (77.8%), unusual in nature (70.7%) and if the reaction was to a new product 
(58.6%) [28]. 
 
HCPs should consider ADR reporting as an obligation [29], especially in view of their potential impact 
on outcomes and costs, which can be appreciably reduced with improved medicine management [3-
5]. At Sebokeng Hospital, 98% of HCPs now indicated that it was necessary to report ADRs, similar to 
the findings from a tertiary hospital in India (97%) [30]. This is encouraging. 
 
Encouraging as well following the intervention, none of the respondents felt that ADR reporting should 
be remunerated, differing from Das et al. [31] where 16.7% of doctors indicated that ADRs were not 
reported because of a lack of remuneration. Ray and Venugopal [30] found that 54.7% of doctors 
disagreed that the absence of ADR reporting was due to a lack of remuneration, although rates could 
be enhanced with remuneration. 
 
Lack of knowledge of where ADRs should be reported also affects reporting rates. A study carried out 
by Gupta and Udopa [32] found a lack of knowledge was the main reason for under-reporting, whilst 
Sabblah et al. [27] reported that training significantly improved ADR reporting (p<0.001). Our training 
and awareness programme (Phase B) appeared to contribute significantly to HCPs gaining 
knowledge about the ADR reporting system, among medical practitioners (p<0.0001), pharmacists’ 
assistants (p=0.0233) and nurses (p<0.0001) (Table 2). The lack of a significant improvement in the 
knowledge of pharmacists about ADRs could be due to the fact that pharmacists are more aware of 
and involved in ADRs of medicines (Table 2). This result is similar to a study conducted in Istanbul 
where the authors found that 89% of pharmacists believed that their role in ADR reporting was 
essential [33]. 
 
Continuous training as part of HCPs’ everyday practice also increased their awareness of ADRs and 
improved reporting rates, with regular retraining carried out during the intervention phase (Figure 1). 
This indicates that regular sensitization of all HCPs on the importance of PV is effective, similar to the 
findings of Li et al. [34], who also showed that educational interventions improved knowledge, 
attitudes and the practise of reporting ADRs. In addition, similar to other studies that have shown 
continuous education of HCPs about PV, including ADRs, through presentations, verbal reminders, 
increased accessibility of report forms in wards, attendance of pharmacists in wards, and actively 
involving HCPs in education and training, improves their knowledge and attitudes about ADRs [27, 
29, 31, 34].  
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It is well known that the beneficial effects of interventions on medical practice tend to decline over 
time. As a result, currently continuous discussion of ADR reporting, with subsequent reminding of 
HCPs to report ADRs, takes place during monthly PTC meetings in the hospital to maintain and also 
further improve ADR reporting at this hospital. However, we have not re-assessed the impact of this.  
 
In order to address some of the determinants of under-reporting found in a study conducted in a 
tertiary centre in Northern Nigeria, it was proposed that ADR reporting guidelines should be made 
available in the form of booklets and posters at conspicuous locations in healthcare facilities to serve 
as a constant reminder [24], with educational interventions shown to improve awareness, attitudes, 
and practices of health-care professionals towards PV [35, 36]. In our study, 52.3% of HCPs indicated 
that they had noticed the posters placed in the wards regarding ADRs; however, only 21.2% indicated 
that the posters actually prompted them to report an ADR (Table 5). The example of a completed 
ADR form placed in the wards was also found useful by over a third of HCPs (35.8%) when 
completing an ADR form, which is encouraging, and is being continued. 
 
We are aware that the study was conducted in only one hospital in the Gauteng Province. 
Consequently, the results cannot be generalizable to all other public sector health care institutions in 
South Africa. We recommend a much larger study to gain a more accurate picture of current ADR 
reporting rates, and ways to improve them, in South Africa across all sectors. However, this initiative 
will take time, especially considering the challenges with operational projects. In-depth interviews 
could also be useful in the future to gain deeper understanding of the opinions and attitudes of the 
HCPs. Furthermore, although the ADR reports submitted by HCPs in this study included information 
necessary for causality assessment, such as the date of drug administration, date of reaction onset, 
outcome at de-challenge of the medication, concomitant medications and concomitant illness, the 
quality of the reports was not assessed. The quality of ADR reporting to enable robust causality 
assessment will be the focus of future studies given the positive findings with this intervention.  
 
We are also aware that due to convenient sampling and the operational nature of the study, there are 
difference in the nature of HCPs taking part in both Phases (A and C) with more physicians taking 
part in Phase C. However, the principal aim was to assess the influence of the interventions rather 
than match respondents between the two samples, especially given the voluntary nature of the study. 
Another limitation was the non-availability of pharmacists to attend ward rounds in all the wards of the 
hospital. Although pharmacists were allocated to the medical wards, their involvement in the ward 
rounds was dependent on their availability according to the time schedule of the pharmacy. This 
should be addressed in the future to further improve ADR reporting rates. Despite these limitations, 
we believe the findings are robust providing future direction to public hospitals in South Africa and 
wider, and our findings are already leading to changes in our hospital regarding the reporting of 
ADRs. 
  
5. Conclusion 
The study strongly indicates that the majority of HCPs did not have appropriate knowledge about the 
hospital’s ADR monitoring and PV programme before the intervention. The implementation of an 
active PV system by a pharmacist proved to be successful in improving ADR monitoring and reporting 
in line with the goals of the National Department of Health in South Africa. ADR reporting was 
increased by creating awareness of an appropriate educational intervention and training on PV 
amongst HCPs, which should reduce future morbidity, mortality and costs among public hospital 
patients in South Africa. These programmes will continue in this hospital together with arguing for a 
greater role of hospital pharmacists to improve patient care in the future. We believe this is one of the 
first studies among public sector hospitals in South Africa to improve knowledge and reporting of 
ADRs, and the findings will be used to guide future activities among this and other public hospitals in 
South Africa. 
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